⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8681998 | 1.00 | — | — | |
| SCHEMBL10296027 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2132348 | 0.98 | SMN1; SMN2 (0.39) | — | |
| Hydrochloric Acid SCHEMBL23201940 | 0.98 | SMN1; SMN2 (0.39) | — | |
| Hydrochloric Acid SCHEMBL6036048 | 0.98 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL120529 | 0.82 | L3MBTL1 (0.46) | — | |
| SCHEMBL112489 | 0.82 | L3MBTL1 (0.46) | — | |
| SCHEMBL120528 | 0.82 | L3MBTL1 (0.46) | — | |
| Hydrochloric Acid SCHEMBL6315039 | 0.80 | L3MBTL1 (0.44) | — | |
| Bromide SCHEMBL8314221 | 0.80 | L3MBTL1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424499-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | claimed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | claimed |
| CN-110475474-B | Compounds and methods of use | 西格纳姆生物科学公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2022004744-A1 | NOVEL HETEROCYCLIC COMPOUND AND SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION | 国立大学法人電気通信大学 | 2022-01-06 | — | — | WO | disclosed |
| CN-105820138-A | ABT-263 crystalline forms and solvates for use in treating BCL-2 protein related diseases | ABBVIE 公司 | 2016-08-03 | — | — | CN | disclosed |
| CN-102802605-B | Stable lipid formulations of apoptosis promoters | ABBVIE (US) | 2015-08-12 | — | — | CN | disclosed |
| US-8927009-B2 | ABT-263 capsule | ABBVIE INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8728516-B2 | Stabilized lipid formulation of apoptosis promoter | ABBVIE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8513243-B2 | ABT-263 crystalline forms | ABBVIE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8362013-B2 | Salt of ABT-263 and solid-state forms thereof | ABBVIE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2010127198-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| EP-0266950-B1 | Nor-statine and nor-cyclostatine polypeptides | PFIZER (US) | 1993-12-29 | — | — | EP | disclosed |
| US-5227398-A | BENZODIOXOLE DERIVATIVES AND HEPATOPATHY IMPROVERS COMPRISING THE SAME | TSUMURA & CO. (JP) | 1993-07-13 | — | — | US | disclosed |
| EP-0488144-A1 | Benzodioxole derivatives and hepatopathy improvers comprising the same | TSUMURA & CO. (JP) | 1992-06-03 | — | — | EP | disclosed |
| US-5034376-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1991-07-23 | — | — | US | disclosed |
| US-4935405-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1990-06-19 | — | — | US | disclosed |
| US-4814342-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1989-03-21 | — | — | US | disclosed |
| EP-0266950-A2 | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1988-05-11 | — | — | EP | disclosed |
| US-4523012-A | INTERMEDIATES FOR PRODUCTION OF D,L-CYSTEINE AND DERIVATIVES | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1985-06-11 | — | — | US | disclosed |